IL299748A - Antibodies that bind PSMA and T gamma delta receptors - Google Patents

Antibodies that bind PSMA and T gamma delta receptors

Info

Publication number
IL299748A
IL299748A IL299748A IL29974823A IL299748A IL 299748 A IL299748 A IL 299748A IL 299748 A IL299748 A IL 299748A IL 29974823 A IL29974823 A IL 29974823A IL 299748 A IL299748 A IL 299748A
Authority
IL
Israel
Prior art keywords
multispecific antibody
seq
set forth
sequence set
antigen
Prior art date
Application number
IL299748A
Other languages
English (en)
Hebrew (he)
Inventor
Cornelis Roovers Robertus
Jelle Van Der Vliet Johannes
Anna King Lisa
Willem Henri Ida Parren Paul
Guimarais Iglesias Victoria
Lutje Hulsik David
Alexander Gerardus Maria Machielsen Peter
Original Assignee
Lava Therapeutics N V
Cornelis Roovers Robertus
Jelle Van Der Vliet Johannes
Anna King Lisa
Willem Henri Ida Parren Paul
Guimarais Iglesias Victoria
Lutje Hulsik David
Alexander Gerardus Maria Machielsen Peter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics N V, Cornelis Roovers Robertus, Jelle Van Der Vliet Johannes, Anna King Lisa, Willem Henri Ida Parren Paul, Guimarais Iglesias Victoria, Lutje Hulsik David, Alexander Gerardus Maria Machielsen Peter filed Critical Lava Therapeutics N V
Publication of IL299748A publication Critical patent/IL299748A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL299748A 2020-07-08 2021-07-08 Antibodies that bind PSMA and T gamma delta receptors IL299748A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20184800 2020-07-08
PCT/EP2021/068960 WO2022008646A1 (en) 2020-07-08 2021-07-08 Antibodies that bind psma and gamma-delta t cell receptors

Publications (1)

Publication Number Publication Date
IL299748A true IL299748A (en) 2023-03-01

Family

ID=71527722

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299748A IL299748A (en) 2020-07-08 2021-07-08 Antibodies that bind PSMA and T gamma delta receptors

Country Status (11)

Country Link
US (2) US20230272110A1 (enExample)
EP (1) EP4178981A1 (enExample)
JP (1) JP2023532807A (enExample)
KR (1) KR20230042035A (enExample)
CN (1) CN116323667A (enExample)
AU (1) AU2021305396A1 (enExample)
BR (1) BR112023000269A2 (enExample)
CA (1) CA3188601A1 (enExample)
IL (1) IL299748A (enExample)
MX (1) MX2023000448A (enExample)
WO (1) WO2022008646A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4544302A1 (en) * 2022-06-23 2025-04-30 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
JP7855148B2 (ja) * 2023-02-10 2026-05-07 アムニクス ファーマシューティカルズ， インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) * 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
WO2001022816A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2514419A1 (en) 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
WO2005046711A2 (en) 2003-11-07 2005-05-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
ATE476497T1 (de) 2004-08-19 2010-08-15 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
ES2386366T3 (es) 2005-02-18 2012-08-17 Medarex, Inc. Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA)
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US8338173B2 (en) 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP1878440A1 (en) 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2009046294A2 (en) 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US8629247B2 (en) 2009-04-14 2014-01-14 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
WO2013110531A1 (en) 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
DK2831109T3 (en) 2012-03-28 2018-02-12 Gadeta B V COMBINATORY GAMMA-9-DELTA-2-T-CELL RECEPTOR CHAIN EXCHANGE
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
EP2850106B1 (en) 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
JP6340006B2 (ja) 2012-10-05 2018-06-06 コーネル ユニヴァーシティー アンドロゲン抑制、前立腺特異的膜抗原、および条件的に増大した脆弱性の概念
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US20160251440A1 (en) 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
TW201639891A (zh) 2015-03-10 2016-11-16 索倫多醫療公司 結合ｐｓｍａ之抗體治療劑
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CN104829730A (zh) 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
EA201792442A1 (ru) 2015-05-06 2018-06-29 Янссен Байотек, Инк. Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
HRP20191800T1 (hr) 2015-05-13 2019-12-27 Ablynx N.V. Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
JP2019506155A (ja) 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ 治療分子
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN109641037B (zh) 2016-04-13 2022-09-06 西安奥瑞单抗生物技术有限公司 抗psma抗体及其用途
EP3450460B1 (en) 2016-04-29 2023-07-12 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
EP3490675A4 (en) 2016-07-29 2020-07-29 New York University T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
KR102275008B1 (ko) * 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
JP7215997B2 (ja) * 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
MA48763A (fr) * 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
KR20200142525A (ko) 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
CN112469440B (zh) 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
CN119143875A (zh) * 2018-06-21 2024-12-17 瑞泽恩制药公司 双特异性抗psma x抗cd28抗体及其用途
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7457007B2 (ja) * 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用ＣＤ１ｄ免疫グロブリン
AU2019356573B2 (en) * 2018-10-11 2025-12-18 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
WO2020159368A1 (en) 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
CA3148588A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
CA3173268A1 (en) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
WO2021183845A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Materials and methods for modulating delta chain mediated immunity
WO2021231434A1 (en) 2020-05-12 2021-11-18 Harpoon Therapeutics, Inc. Psma targeting tritacs and methods of use
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
US12076413B2 (en) 2020-10-28 2024-09-03 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
MX2023006832A (es) 2020-12-10 2023-08-22 Lava Therapeutics N V Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
CN118317791A (zh) 2021-03-09 2024-07-09 哈普恩治疗公司 使用免疫细胞衔接蛋白和免疫调节剂的组合疗法

Also Published As

Publication number Publication date
AU2021305396A1 (en) 2023-02-09
MX2023000448A (es) 2023-04-20
EP4178981A1 (en) 2023-05-17
BR112023000269A2 (pt) 2023-03-28
US20230272110A1 (en) 2023-08-31
US20240317888A1 (en) 2024-09-26
CA3188601A1 (en) 2022-01-13
KR20230042035A (ko) 2023-03-27
WO2022008646A1 (en) 2022-01-13
CN116323667A (zh) 2023-06-23
US12428493B2 (en) 2025-09-30
JP2023532807A (ja) 2023-07-31

Similar Documents

Publication Publication Date Title
US12428493B2 (en) Antibodies that bind PSMA and gamma-delta T cell receptors
JP7447208B2 (ja) 抗体
TW202128757A (zh) 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
KR20230157933A (ko) 감마-델타 t 세포 수용체에 결합하는 항체
WO2022171080A1 (zh) 抗cd112r抗体及其用途
WO2023115528A1 (en) Antibodies against mesothelin and uses thereof
KR20250171367A (ko) Steap2 지향성 t 세포 결합제 및 이의 조성물
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
CN113214402A (zh) 分离的抗原结合蛋白及其应用
JP2025524347A (ja) ガンマデルタｔ細胞受容体に結合するバリアント抗体
CN114539420A (zh) 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
EP4714975A1 (en) Antibody binding lilrb4 and cd3, and use thereof
US20250109204A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
EA048596B1 (ru) Антитела, которые связывают psma и гамма-дельта рецепторы т-клеток
US12545732B2 (en) PD-1 antigen-binding protein and use thereof
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
CN119345349A (zh) 抗ox40抗体在制备药物中的用途
EA053202B1 (ru) Антитела, которые связывают гамма-дельта т-клеточные рецепторы
KR20240046557A (ko) 항-b7-h4 항체 및 이의 제조 방법과 용도
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
HK40118288A (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
TW202523698A (zh) 抗ｇｐｒｃ５ｄ抗體及組成物
WO2025092742A1 (zh) 结合bcma的抗体以及包含其的多特异性抗体
CN119213034A (zh) 双功能蛋白质及其制剂和用途